Sign In
Buy AVTX
$13.74
-0.220 (-1.58%)
At Close: Jun 03, 2026
Avalo Therapeutics Announces Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 22'nd May 2026
WAYNE, PA., May 22, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for immune-mediated i
Avalo Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Updates
07:00am, Wednesday, 13'th May 2026
WAYNE, Pa., May 13, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for imm
Avalo Therapeutics Announces Pricing of $375 Million Public Offering
11:33pm, Tuesday, 05'th May 2026
WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for imm
Avalo Therapeutics Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
04:05pm, Tuesday, 05'th May 2026
WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (NASDAQ: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for imm
WAYNE, Pa., May 05, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX), a clinical stage biotechnology company fully dedicated to developing IL-1β based treatments for immune-mediated i
Avalo Therapeutics Purchases Optional Milestone Buyout
07:00am, Tuesday, 28'th Apr 2026
WAYNE, Pa., April 28, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical-stage biotechnology company fully dedicated to developing IL-1β based treatments for i
Brokerages Set Avalo Therapeutics, Inc. (NASDAQ:AVTX) Target Price at $42.25
01:25am, Tuesday, 07'th Apr 2026
Avalo Therapeutics, Inc. (NASDAQ: AVTX - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the eight brokerages that are presently covering the firm, Marketbeat.com reports.
Pre-Market Stock Futures: Futures are trading mixed as we get ready to kick off the first-quarter earnings season next week, and, as usual, the big money-center banks and brokerage firms will headline
Avalo Therapeutics (NASDAQ:AVTX) Insider Sells $10,864.00 in Stock
05:43am, Monday, 06'th Apr 2026
Avalo Therapeutics, Inc. (NASDAQ: AVTX - Get Free Report) insider Mittie Doyle sold 679 shares of the firm's stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of
Wall Street Analysts Predict an 113.34% Upside in Avalo Therapeutics (AVTX): Here's What You Should Know
10:56am, Friday, 03'rd Apr 2026
The average of price targets set by Wall Street analysts indicates a potential upside of 113.3% in Avalo Therapeutics (AVTX). While the effectiveness of this highly sought-after metric is questionable
5 Small Drug Stocks to Buy as Sector Recovery Gains Strength
11:01am, Thursday, 02'nd Apr 2026
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, CPRX, TBPH, RLMD and AVTX may prove to be good additions to one's portfolio.
Avalo Therapeutics Reports 2025 Financial Results and Recent Business Updates
07:00am, Monday, 23'rd Mar 2026
WAYNE, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: AVTX) (“Avalo”), a clinical stage biotechnology company fully dedicated to developing IL-1β-based treatments for i
Ally Bridge Group NY LLC Purchases New Position in Avalo Therapeutics, Inc. $AVTX
03:31am, Sunday, 15'th Mar 2026
Ally Bridge Group NY LLC acquired a new position in Avalo Therapeutics, Inc. (NASDAQ: AVTX) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. T
Avalo Therapeutics CEO Teases Q2 Top-Line Data for AVTX-009 Phase 2b HS LOTUS Trial at Conference
01:14am, Saturday, 14'th Mar 2026
Avalo Therapeutics (NASDAQ: AVTX) CEO Garry Neil said the company expects to report top-line data in the second quarter from its completed Phase 2b LOTUS trial of AVTX-009 in hidradenitis suppurativa
Silence Therapeutics (NASDAQ:SLN) versus Avalo Therapeutics (NASDAQ:AVTX) Head-To-Head Comparison
04:26am, Wednesday, 11'th Mar 2026
Avalo Therapeutics (NASDAQ: AVTX - Get Free Report) and Silence Therapeutics (NASDAQ: SLN - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the
